A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA.
about
The Potential Dangers of Using MDMA for PsychotherapyAbuse of amphetamines and structural abnormalities in the brainHallucinogens: An updateNeural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)Pharmacological treatment of anxiety disorders: current treatments and future directionsEcstasy: are animal data consistent between species and can they translate to humans?Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug useHuman psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.Flashback to the 1960s: LSD in the treatment of autism.Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.The role of MDMA (Ecstasy) in coping with negative life situations among urban young adults.A developmental comparison of the neurobehavioral effects of ecstasy (MDMA)MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.Neuroimaging research in human MDMA users: a review.Neurogenic bladder and chronic urinary retention associated with MDMA abuseThe psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen PharmacologyOxytocin receptor gene variation predicts subjective responses to MDMA.Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.Anxiolytic drug discovery: what are the novel approaches and how can we improve them?MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions.Cocaine and MDMA Induce Cellular and Molecular Changes in Adult Neurogenic Systems: Functional Implications.High ambient temperature facilitates the acquisition of 3,4-methylenedioxymethamphetamine (MDMA) self-administration.(±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.MDMA induces EPSP-Spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors.Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study
P2860
Q21558619-5DC88141-D6AC-45FB-91DB-96D36FBF996FQ22241673-3BAFB5F7-7E77-423F-8418-804EE0D2EF3AQ22252593-57E6317C-81D2-4C3A-9964-E779CA4A1547Q24619949-516A5CAC-3F0B-4026-98A6-15F20DB3AE6AQ26851461-53D9AFBC-ED09-448C-975C-1223740089A3Q31033315-634F045D-3C9F-4238-9707-E2BD2B87721FQ33707843-22282332-9F61-479E-AC60-B56A0945A686Q34359604-CDB76F11-213B-44BC-8F1D-F5D1EF84E806Q34407992-93B0AC74-2A07-4134-B068-30EA7B657F1BQ34420092-18F3E080-8A06-4C85-B700-DEFD3146B641Q34502080-C34A24C5-C902-4A81-BF6B-7259D0CB3C2FQ34565712-4FF48AA9-E593-43F1-AC32-E86B14CCCC1FQ34645389-DFD62AA8-1C27-44CD-8AA8-9C36D25E2DA4Q34976260-8399A234-9008-47A3-80FE-86B01CAD6CF9Q35607083-6234A6A8-E560-4CEB-86B9-EB969C3BFEF8Q35851128-2C231192-4AD4-4F9E-806E-906DE6527D60Q36410784-6D19EA6E-5D7E-4156-AC60-196386F35062Q36539089-6A0001FE-20F4-44C6-99A4-130A86161250Q36548689-E1BB357D-E16D-47F7-80FD-DF1FF0F2A79BQ36734781-83AE62C7-D799-460D-BB51-47981FB1900FQ37113859-1A4E1592-373F-44DF-8524-40FD620E7B7DQ37149027-D5D898AE-C035-4DF0-A6B2-F0245D9D8787Q37184290-FBF46BF7-34A0-41A8-86A9-CDDCA8D5DC04Q37315499-2D8760DF-08F4-493C-AF98-F906B592A95FQ38160918-67701FFA-5356-4A7E-B724-F1877FB52649Q40028400-A35D93B9-3AAF-42F4-AE27-A9820A456EAEQ40360036-0FEE8A74-FD20-4F6A-A75D-BC747B8F959CQ40530195-210DC5C8-020A-4CC0-91C6-11FE511EAB3FQ46121383-7C7D8690-257A-4F02-A079-13C234379481Q47312691-2A320FF8-B740-453F-B4C7-58ACC11E31C8Q47777762-FFE959E5-47CF-46FB-ADB6-5B64C5A28241Q48095503-A9D7DA89-C19C-4ED6-A0D3-18F941045542Q51482161-7FAC8992-6884-4839-82FB-DFF78D976E3DQ52803481-4E7A00DC-8BDC-4F9D-9123-07A5F89D7ACFQ56069771-D5B1B89C-3B36-41F7-8A2D-3DF469781C06
P2860
A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@ast
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@en
A clinical plan for MDMA
@nl
type
label
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@ast
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@en
A clinical plan for MDMA
@nl
prefLabel
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@ast
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@en
A clinical plan for MDMA
@nl
P2860
P1476
A clinical plan for MDMA (Ecst ...... TSD): partnering with the FDA.
@en
P2093
Rick Doblin
P2860
P304
P356
10.1080/02791072.2002.10399952
P577
2002-04-01T00:00:00Z